New and Novel Therapies for Gynecologic Cancers

Semin Oncol Nurs. 2019 Apr;35(2):217-219. doi: 10.1016/j.soncn.2019.02.009. Epub 2019 Mar 12.

Abstract

Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies.

Data sources: PubMed, FDA.gov, ASCO.org.

Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies.

Implications for nursing practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

Keywords: bevacizumab; cervical cancer; endometrial cancer; ovarian cancer; parp inhibitors; pembrolizumab.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Drug Approval
  • Female
  • Genital Neoplasms, Female / classification
  • Genital Neoplasms, Female / drug therapy*
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents